Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07604233
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Fludarabine — DRUGGiven by IV
- Cytarabine — DRUGGiven by IV
- Idarubicin — DRUGGiven by IV
- Filgrastim — DRUGGiven by injection
- Venetoclax — DRUGGiven by orally
- Asciminib — DRUGGiven orally
- Blinatumomab — DRUGGiven by IV
Study Details
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML. The goal of Phase 2 is to learn if asciminib in combination with FLAG-Ida and venetoclax can help to control the disease.
Key Dates
- Start date
- Nov 30, 2026
- Status verified
- Jun 2026
- Primary completion
- Jun 3, 2031
- Completion
- Jun 3, 2033
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment with FLAG-Ida + Venetoclax + Asciminib
- Experimental: Treatment with FLAG-Ida + Venetoclax + Asciminib + Blinatumomab
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Fadi Haddad, MD346-234-4135
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT MD Anderson | Houston | Texas | 77030 | Fadi Haddad, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By condition
By specialty
By research site
Related Studies
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLPHASE1 · Recruiting · Ascentage Pharma Group Inc. · Birmingham, Alabama
- Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT SurvivorsPHASE2 · Recruiting · Children's Hospital of Philadelphia · Duarte, California
- Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaPHASE1 · Recruiting · University of Colorado, Denver · Aurora, Colorado
- Halt Aging in Survivors of Blood CancersPHASE2 · Recruiting · University of Nebraska · Omaha, Nebraska